Our team acted as lead counsel for a large long-term care company named as a defendant in a False Claims Act (FCA) qui tam action involving allegations of medically unnecessary services and improper billing. After conducting an internal investigation, we successfully advocated that the allegations lacked merit, thus leading the Department of Justice and a State Attorney General’s Office to decline to intervene in the matter.
Successful Declination of Qui Tam for Long-Term Care Company
You Also May Be Interested In:
Representation of Life Sciences Company Fagron Holding USA LLC
Representation of axialHealthcare, a care optimization platform navigating substance use issues for patients, providers, and health plans, in a $15 million Series C round of financing to accelerate its expansion into the substance use disorder (SUD) treatment, and recovery sector. Previous institutional investors Oak HC/FT, .406 Ventures, BlueCross BlueShield Venture Partners (BCBSVP), and Sandbox Advantage Fund led the round.